

# Gut

An International Journal of  
Gastroenterology and Hepatology

OCTOBER 2000 VOLUME 47 NUMBER 4

## Leading article

459 ERCP training—time for change *M D Hellier, A I Morris*

## Commentaries

461 No *H pylori*: less dyspepsia? *K E L McColl*

462 Non-Hodgkin's lymphoma after immunosuppressive therapy *L J Kinlen*

463 Colorectal cancer survival in Europe: the Will Rogers phenomenon revisited *M Shahrier, D J Ahnen*

## Science @lert

465 Specific targeting of IL-6 signalling pathway: a new way to treat IBD? *P Desreumaux*

## Stomach

467 Acute gastritis with hypochlorhydria: report of 35 cases with long term follow up *W V Harford, C Barnett, E Lee, G Perez-Perez, M J Blaser, W L Peterson*

473 Short course acid suppressive treatment for patients with functional dyspepsia: results depend on *Helicobacter pylori* status *A L Blum, R Arnold, M Stolte, M Fischer, H R Koelz, Frosch Study Group*

481 Expression of leptin and leptin receptor isoforms in the human stomach *H Mix, A Widjaja, O Jandl, M Cornberg, A Kaul, M Göke, W Beil, M Kuske, G Brabant, M P Manns, S Wagner*

## Inflammatory bowel disease

487 Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics *E A Vasilias, L Y Kam, L C Karp, J Gaiennie, H Yang, S R Targan*

497 Perceptual responses in patients with inflammatory and functional bowel disease *L Chang, J Munakata, E A Mayer, M J Schmulson, T D Johnson, C N Bernstein, L Saba, B Naliboff, P A Anton, K Matin*

506 A simple method for assessing intestinal inflammation in Crohn's disease *J Tibble, K Teahon, B Thjodleifsson, A Roseth, G Sigthorsson, S Bridger, R Foster, R Sherwood, M Fagerhol, I Bjarnason*

514 Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low *R J Farrell, Y Ang, P Kileen, D S O'Briain, D Kelleher, P W N Keeling, D G Weir*

## Small intestinal disease

520 Immune reaction against the cytoskeleton in coeliac disease *M G Clemente, M P Musu, F Frau, G Brusco, G Sole, G R Corazza, S De Virgiliis*

527 COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin *G Sigthorsson, R Crane, T Simon, M Hoover, H Quan, J Bolognese, I Bjarnason*

## Colorectal disease

- 533 Understanding variations in survival for colorectal cancer in Europe: a EURO CARE high resolution study  
*G Gatta, R Capocaccia, M Sant, C M J Bell, J W W Coebergh, R A M Damhuis, J Faivre, C Martinez-Garcia, J Pawlega, M Ponz de Leon, D Pottier, N Raverdy, E M I Williams, F Berrino*

## Pancreatitis

- 539 Sphincter of Oddi dysfunction produces acute pancreatitis in the possum *J W C Chen, A Thomas, C M Woods, A C Schlothe, J Toubli, G T P Saccone*
- 546 Inflammatory mediators in human acute pancreatitis: clinical and pathophysiological implications *J Mayer, B Rau, F Gansauge, H G Beger*

## Liver disease

- 553 TNF- $\alpha$  dependent production of inducible nitric oxide is involved in PGE<sub>1</sub> protection against acute liver injury *J Muntané, F J Rodríguez, O Segado, A Quintero, J M Lozano, E Siendones, C A Pedraza, M Delgado, F O'Valle, R García, J L Montero, M De la Mata, G Miño*
- 563 Assessment of efficiency and safety of adenovirus mediated gene transfer into normal and damaged murine livers *T Nakatani, S Kuriyama, K Tominaga, T Tsujimoto, A Mitoro, M Yamazaki, H Tsujinoue, H Yoshiji, S Nagao, H Fukui*
- 571 Effect of L-ornithine-L-aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial *C J Rees, K Oppong, H Al Mardini, M Hudson, C O Record*
- 575 HFE gene mutation (C282Y) and phenotypic expression among a hospitalised population in a high prevalence area of haemochromatosis *S Distanto, J P Berg, K Lande, E Haug, H Bell*

## Case report

- 580 Laser Doppler flowmetry is useful in the clinical management of small bowel transplantation *E J Corbett, B N Barry, S G Pollard, J P A Lodge, M C Bellamy, and on behalf of the Liver Transplant Group*

## Gut file

- 584 Acute *Fasciola hepatica* infection attributed to chewing khat *A Cats, P Scholten, S G M Meuwissen, E J Kuipers*

## Occasional Viewpoint

- 586 PBC: an infectious disease? *G H Haydon, J Neuberger*

## Review

- 589 Mucins and mucosal protection in the gastrointestinal tract: new prospects for mucins in the pathology of gastrointestinal disease *A P Corfield, N Myerscough, R Longman, P Sylvester, S Arul, M Pignatelli*

## Letters to the editor

- 595 Liver disease and pulmonary hypertension *S S Salvi*
- 595 UDCA, PBC, and biochemistry, what does normal mean? *M Leuschner*
- 596 Endoscopic gastrin test and *Helicobacter pylori* infection *V Savarino, C Mansi, S Vigneri*
- 596 Losartan and renal sodium handling *R J Alan, D E Newby*
- 597 Replication error phenotype in colorectal cancer *J R Jass*
- 598 Fibrosing colonopathy in an adult caused by over use of pancreatic enzyme supplements *M Häusler, G Heimann, R Meilicke, S Biesterfeld*
- 598 Coeliac disease and unfavourable outcome of pregnancy *D J Unsworth, R J Lock, N Haslam*
- 599 **Book reviews** **Notes**

**Cover illustration:** Immunohistochemical detection of leptin in serial sections of human fundic mucosal biopsies ( $\times 400$ ). (From the paper by Mix *et al*, pp 481–6.)